Abstract
In this work, we report a systematic review and meta-analysis that seeks to analyze the accuracy of diagnostic tests for coronavirus disease 2019 (COVID-19). The objective of this article is to detail the scientific findings based on diagnostic tests of the last years when the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred. Searches for published studies were carried out in the PubMed database between the years 2020 and 2021 for the diagnosis of COVID-19. Ninety-nine scientific articles that met the criteria were examined and accepted in the meta-analysis, and the diagnostic accuracy was evaluated through specificity and sensitivity. Molecular tests [Reverse transcription polymerase chain reaction (RT-PCR), reverse transcription loop-mediated isothermal amplification (RT-LAMP), and clustered regularly interspaced short palindromic repeats (CRISPR)] showed better performance in terms of sensitivity and specificity when compared to serological tests [Enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), lateral flow immunoassay (LFIA), chemiluminescent microparticle immunoassays (CMIA), and Fluorescence immunoassay (FIA)], which showed higher specificity, mainly for the detection of IgG antibodies; however, they showed sensitivity <90%. In addition, the antiviral neutralization bioassay (ANB) diagnostic test demonstrated high potential for the diagnosis of COVID-19, since it obtained the highest area under the curve restricted to the false-positive rates (AUCFPR) of 0.984. It is settled that the different diagnostic tests have been efficiently adapted for the detection of SARS-CoV-2; however, their performance still needs to be optimized to control future outbreaks of COVID-19, which will also serve to help the control of future infectious agents.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by Universidad Catolica de Santa Maria (grants 27574-R-2020, and 28048-R-2021)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data employed in the study was obtained from previously published research articles
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- ACE2
- Angiotensin-converting enzyme 2
- ANB
- Antiviral neutralization bioassay
- AUC
- Area Under the Curve
- AUCFPR
- Area Under the Curve Restricted to The False Positive Rates
- BS
- Biosensors
- CI
- Confidence interval
- CLIA
- Chemiluminescence immunoassay
- CMIA
- Chemiluminescent microparticle immunoassay
- COVID-19
- Coronavirus disease
- CRISPR
- Clustered regularly interspaced short palindromic repeats
- DOR
- Diagnostic Likelihood Ratio
- ECLIA
- Electrochemiluminescence immunoassay
- ELISA
- Enzyme-Linked Immunosorbent Assay
- FIA
- Fluorescence immunoassay
- FN
- False negatives
- FP
- False positives
- IgA
- Immunoglobulin A
- IgG
- Immunoglobulin G
- IgM
- Immunoglobulin M
- INPLASY
- International Platform of Registered Systematic Review and Meta-analysis Protocols
- LFIA
- Lateral flow immunoassay
- LR-
- Negative Likelihood Ratio
- LR+
- Positive Likelihood Ratio
- MA
- Microarrays
- MeSH
- Medical Subject Headings
- NCBI
- National Center for Biotechnology Information
- NGS
- Next-generation sequencing
- PRISMA
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- ROC
- Receiver Operating Characteristics
- RT-LAMP
- Reverse transcriptase loop-mediated isothermal amplification
- RT-PCR
- Reverse transcription–polymerase chain reaction
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- Se
- Sensibility
- Sp
- Specificity
- sROC
- Summary Receiver Operating Characteristics
- TN
- True negatives
- TP
- True positives
- WHO
- World Health Organization
